BeiGene (ONC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of America Securities maintained a Buy rating on the stock and has a $300.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
David Li has given his Buy rating due to a combination of factors including BeiGene’s strong sales performance and promising product pipeline. The company’s self-developed drugs, such as tislelizumab and zanubrutinib, have shown significant year-over-year and month-over-month growth in sales, indicating robust demand and market penetration.
Additionally, BeiGene’s licensed-in products have also contributed positively to its sales figures, further supporting the company’s financial health. The analyst also highlights the company’s leadership in the BTK inhibitor market in China, with zanubrutinib capturing a substantial share. These factors, along with the company’s on-track clinical progress, underpin the optimistic price objective of $300, making BeiGene a compelling investment opportunity.
In another report released on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $334.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue